Payment overview · 2025
General Payments
$425.59
23 reported records · 15 companies
Healthcare provider profile · identity verified
Andrew Chema, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MEDINA, OH · NPI 1053572560
Verified facts
What the public records show
CMS Open Payments records show Andrew Chema, M.D. received $425.59 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.29 | 13.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.79 | 12.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.78 | 10.8% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $40.43 | 9.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.57 | 8.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.96 | 7.7% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.64 | 6.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.45 | 5.7% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $18.67 | 4.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.27 | 4.1% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.96 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.23 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.99 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.71 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.85 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $425.59 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.79 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.79 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $26.55 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 169 |
| Lisinopril | Lisinopril | 373 | 104 |
| Gabapentin | Gabapentin | 300 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 75 |
| Losartan Potassium | Losartan Potassium | 224 | 59 |
| Omeprazole | Omeprazole | 218 | 65 |
| Trazodone Hcl | Trazodone Hcl | 211 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 49 |
| Metformin Hcl | Metformin Hcl | 171 | 44 |
| Simvastatin | Simvastatin | 171 | 36 |
| Metformin Hcl Er | Metformin Hcl | 143 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 32 |
| Sertraline Hcl | Sertraline Hcl | 91 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 21 |
| Furosemide | Furosemide | 78 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 62 |
| Januvia | Sitagliptin Phosphate | 72 | 17 |
| Prednisone | Prednisone | 72 | 63 |
| Buspirone Hcl | Buspirone Hcl | 70 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 21 |
| Montelukast Sodium | Montelukast Sodium | 68 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 19 |
| Methylprednisolone | Methylprednisolone | 58 | 56 |
| Meloxicam | Meloxicam | 57 | 18 |
| Atenolol | Atenolol | 54 | 13 |
| Azithromycin | Azithromycin | 54 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 12 |
| Allopurinol | Allopurinol | 52 | 18 |
| Glipizide | Glipizide | 52 | 15 |
| Carvedilol | Carvedilol | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 16 |
| Potassium Chloride | Potassium Chloride | 51 | 15 |
| Spironolactone | Spironolactone | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Chlorthalidone | Chlorthalidone | 48 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 14 |
| Lactated Ringers | Ringer's Solution,lactated | 45 | suppressed |
| Celecoxib | Celecoxib | 43 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Finasteride | Finasteride | 41 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 18 |
| Famotidine | Famotidine | 39 | 14 |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 13 |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 13 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 32 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 13 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $425.59 · 23 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, ETERNA, FREESTYLE LIBRE 2, Fibroscan, INJECTAFER, INSPIRE, Korlym, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error